Comparative Pharmacology
Head-to-head clinical analysis: MAOLATE versus RALDESY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAOLATE versus RALDESY.
MAOLATE vs RALDESY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MAOLATE is a centrally acting muscle relaxant that does not directly relax skeletal muscle. Its mechanism of action is not fully understood, but it is thought to act via inhibition of polysynaptic reflexes at the spinal level and possibly through sedation.
Selective beta-3 adrenergic receptor agonist; relaxes detrusor smooth muscle during storage phase of urinary bladder fill cycle, increasing bladder capacity and reducing urgency.
250 mg orally 4 times daily or 500 mg orally 3 times daily for 21 days; maximum daily dose 2000 mg.
Intravenous: 1 mg/kg every 8 hours; maximum single dose 100 mg.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours (prolonged in renal impairment, up to 20-30 hours in severe renal failure; dose adjustment required for CrCl <30 mL/min)
4-6 hours in adults; prolonged to 8-12 hours in elderly or renal impairment (CrCl <30 mL/min)
Renal: ~70% as unchanged drug and metabolites; Biliary/Fecal: ~30%
Primarily renal (85-90%) with 60% unchanged; biliary/fecal (10-15%)
Category C
Category C
Muscle Relaxant
Muscle Relaxant